Application of nuciferine in preparation of anti-alopecia and hair-growing medicine

Abstract

The invention provides nuciferine and application of physiologically acceptable salts or solvates thereof in preparation of anti-alopecia and hair-growing medicines, and belongs to the technical field of medicines. The medicine disclosed by the invention can promote hair growth, is used for preventing and / or treating alopecia after chemotherapy and preventing and / or treating androgen alopecia, is safe and effective, and has no adverse reaction; the nuciferine can be extracted from plants, has the advantages of being wide in source, low in cost, economical and practical, and has wide application prospects in the fields of pharmaceutical preparations, cosmetics, care products, beauty products and the like.

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to the use of nuciferine and its physiologically acceptable salts or solvates in the preparation of anti-hair loss and hair growth drugs, and further application in the fields of cosmetics, care products, beauty products, etc. Background Art

[0002] Alopecia refers to the loss of hair. Examples of hair loss include male pattern baldness (an androgen-dependent genetic disorder), alopecia areata (a sudden, patchy, non-scarring hair loss), traction alopecia (due to physical traction or pressure on the scalp), dermatophytosis (a dermatophyte infection of the scalp), and trichotillomania (a condition in which patients repeatedly pull out their own hair).

[0003] The hair growth cycle includes the growth phase, the regression phase, and the resting phase. Growth phase (2 to 6 years), regression phase (3 weeks), and resting phase (2-3 months). Hair loss associated with the disorder of the hair follicle growth cycle includes growth phase effluvium and telogen effluvium. Among them, hair loss caused by chemotherapy belongs to growth phase effluvium. While chemotherapy drugs kill tumor cells, they also kill a variety of rapidly proliferating cells, including hair follicle keratinocytes, leading to hair loss. The problem of hair loss after chemotherapy has not yet been solved, and there is currently no special way to alleviate the phenomenon of hair loss caused by chemotherapy. Androgenic alopecia is an androgen-dependent hereditary disease characterized by a shortened growth phase and a prolonged resting phase. Testosterone and dihydrotestosterone are the two main androgens. Testosterone produces dihydrotestosterone under the action of 5α-reductase, which eventually causes the hair to become thinner and softer, causing hair loss.

[0004] Currently, the two main drugs on the market for the treatment of hair loss are minoxidil and finasteride. Minoxidil is an external-use medication that activates hair follicles and shortens the hair resting phase. However, it may cause some side effects, such as accelerated hair loss, increased body hair, and dandruff. Some studies have shown that minoxidil may accelerate hair regrowth after chemotherapy hair loss, but more research is needed to confirm this. Finasteride is an oral medication that can fundamentally improve hair follicle damage caused by androgens. However, due to its inhibition of androgens, it may cause sexual and psychological side effects. Therefore, there is an urgent need to find safer, more effective, and affordable treatments.

[0005] Nuciferine, CAS: 475-83-2, molecular formula C 19 H 21 NO2; Nuciferol is an alkaloid active substance extracted from lotus leaves, which has multiple biological functions, such as reducing fat and weight, antibacterial and anti-inflammatory, and anti-oxidation. [1]In recent years, health problems caused by obesity have received great attention, so the lipid-regulating and weight-loss effects of lotus leaf alkaloids have become a research hotspot. Its structural formula is:

[0006]

[0007] However, there is no document publicly reporting the application of nuciferine and its physiologically acceptable salts or solvates in hair loss and hair growth.

[0008] [1] Tan Yiding, Deng Fangming. Research progress on lotus leaf components and biological functions[J]. Food Research and Development, 2020, 41(10): 193-197. Summary of the invention

[0009] One object of the present invention is to provide a use of nuciferine and its physiologically acceptable salts or solvates in the preparation of anti-hair loss and hair growth drugs. The nuciferine and its physiologically acceptable salts or solvates disclosed in the present invention are safe and effective hair growth active substances that can meet the nursing, therapeutic and cosmetic effects. Specifically, the present invention provides the use of nuciferine and its physiologically acceptable salts or solvates in the preparation of anti-hair loss and hair growth drug preparations; and the use of nuciferine and its physiologically acceptable salts or solvates in the preparation of various cosmetics, care products and beauty products.

[0010] The invention provides use of nuciferine and physiologically acceptable salts or solvates thereof in preparing anti-hair loss and hair growth medicines.

[0011] Nuciferol promotes hair growth in mice with hair plucking. After hair plucking, the hair length and weight of the back hair of the mice were measured on the 14th day of administration. Compared with the model group, nuciferol increased hair length and promoted hair growth, and the effect of 1.5% nuciferol on hair weight was better than that of the minoxidil group. In addition, nuciferol can increase the expression level of related growth factor genes, stimulate cell growth, promote cell survival, and thus promote hair growth.

[0012] When preparing a drug for treating diseases related to hair loss, nuciferine and its physiologically acceptable salts or solvates are used as active ingredients, and the drug is applied to a pharmaceutical preparation; the pharmaceutical preparation is applied to prevent, care for and treat thin hair, hair loss and promote hair health and growth.

[0013] The pharmaceutical preparation comprises nuciferine and its physiologically acceptable salt or solvate and a pharmaceutically acceptable carrier or auxiliary material.

[0014] The pharmaceutically acceptable carrier (e.g., a biocompatible material) may optionally include a surfactant, an excipient, a humectant, an emulsifier, a suspending agent, a salt or a buffer for adjusting the osmotic pressure, a colorant, a flavor, a stabilizer, a bactericide, a preservative or other conventional supplements.

[0015] The dosage form of the drug is cream, patch, ointment, cream preparation, gel or spray.

[0016] The dosage form of the drug can also be tablets, granules, capsules, oral liquid preparations, pills, suspensions or dripping pills.

[0017] When treating diseases related to hair loss, nuciferine and its physiologically acceptable salts or solvates are used as active ingredients. They can be applied topically to the skin, such as creams, patches, ointments, cream preparations, gels and sprays, etc., or they can be taken orally (i.e., oral preparations), such as tablets, granules, capsules, oral liquid preparations, pills, suspensions, pellets, etc.

[0018] The nuciferine and its physiologically acceptable salt or solvate account for 0.1-10 wt % of the total weight of the preparation.

[0019] The medicine of the present invention can be used for preventing and / or treating alopecia after chemotherapy.

[0020] Nuciferol can inhibit alopecia caused by chemotherapeutic agents, resist chemotherapy toxicity and prevent alopecia in chemotherapy-induced alopecia. Hair loss reached its peak on the 5th day after cyclophosphamide injection, and hair growth scores and hair length and weight were measured on the 6th day. Compared with the model group, nuciferol increased hair growth scores and increased hair length and weight in a dose-dependent manner, and the effect of nuciferol was better than minoxidil.

[0021] The medicine of the present invention can also be used for preventing and / or treating androgenic alopecia.

[0022] Nuciferine can inhibit androgens, stimulate the proliferation of hair follicle papilla cells and hair growth, thereby preventing or treating androgenic alopecia. After daily application of androgen modeling and administration for 14 days, nuciferine increased hair length and weight in a dose-dependent manner compared with the model group, and 1.5% nuciferine was more effective than minoxidil.

[0023] The drug of the present invention can also be used in cosmetics, care products or beauty products. The cosmetics, care products or beauty products use nuciferine and its physiologically acceptable salts or solvates as active ingredients.

[0024] The cosmetics, care products or beauty products can be selected from shampoo, hair conditioner, hair essence, hair oil, hair lotion, scalp cream, hair gel, hair spray, hair mask, eyebrow care solution and the like.

[0025] The drug of the present invention stimulates hair growth; the stimulation of hair growth includes accelerating the natural growth rate of hair, increasing hair length and weight, and promoting the growth of existing hair in a healthy state; the drug stimulates the expression and synthesis of growth factors, stimulates cell growth, promotes cell survival, and promotes hair growth.

[0026] The beneficial effects of the present invention are as follows: the nuciferine and its physiologically acceptable salt or solvate of the present invention can effectively promote hair growth in androgenic and chemotherapy alopecia areas, are safe and effective, and have no adverse reactions; they open up new uses of nuciferine and its physiologically acceptable salt or solvate, and provide new options for the preparation of anti-hair loss and hair growth drugs. Moreover, the nuciferine and its physiologically acceptable salt or solvate of the present invention can be extracted from plants, have a wide range of sources, are low in cost, and are economical and affordable, and are very convenient to use as drugs for the preparation of androgenic alopecia and chemotherapy alopecia drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 This is the effect of nuciferine on hair length in natural hair growth model mice.

[0028] Figure 2 The effect of nuciferine on gross weight in natural hair growth model mice.

[0029] Figure 3 The changes in skin growth factor gene expression induced by nuciferine in natural hair growth model mice.

[0030] Figure 4 The effect of nuciferine on hair growth in the cyclophosphamide-induced chemotherapy-induced alopecia C57BL / 6 mouse model.

[0031] Figure 5 Effects of nuciferine on hair length in the cyclophosphamide-induced chemotherapy-induced alopecia C57BL / 6 mouse model.

[0032] Figure 6 Effects of nuciferine on gross weight in a cyclophosphamide-induced chemotherapy-induced alopecia C57BL / 6 mouse model.

[0033] Figure 7 The study demonstrates the hair growth promoting effect of nuciferine in the testosterone-induced androgenic alopecia C57BL / 6 mouse model.

[0034] Figure 8 The effect of nuciferine on gross weight in the testosterone-induced androgenic alopecia C57BL / 6 mouse model. DETAILED DESCRIPTION

[0035] The technical solution of the present invention is described in detail below through specific embodiments, but the protection scope of the present invention is not limited to the embodiments.

[0036] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0037] The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are commercially available products unless otherwise specified.

[0038] Unless otherwise specified, "%" in the examples refers to mass percentage.

[0039] Example 1 Experimental evaluation of the therapeutic effect of nuciferine on the natural hair growth model of C57BL / 6J mice

[0040] 1. Experimental Animals

[0041] The experimental animals were male C57BL / 6J, 7-8 weeks old, weighing 20-24g. C57BL / 6J mice were raised under normal conditions, with a temperature of 25±2℃, a humidity of 50%-70%, and alternating light and dark for 12h each. They were free to eat and drink, and the corncob bedding was changed every two days. The experiment began after they had adapted to the breeding environment for 7 days.

[0042] 2. Drug preparation

[0043] 4% chloral hydrate: weigh 0.8g chloral hydrate and pour into a 20ml centrifuge tube. Add 19.2ml normal saline and dissolve it evenly to prepare a 4% chloral hydrate solution. Prepare and use it immediately.

[0044] The topical cream of nuciferine (concentration: 0.5%, 1.0%, 1.5%) is made from the following raw materials:

[0045] Take 50, 100, and 150 parts by weight of nuciferine, 1000 parts by weight of stearic acid, 200 parts by weight of glyceryl stearate, 200 parts by weight of beeswax, 200 parts by weight of palm oil, 600 parts by weight of butylene glycol, 200 parts by weight of ethanol, 4800 parts by weight of water, and 2 parts by weight of triethanolamine, respectively. According to the above raw material components, the external cream of the present invention is prepared:

[0046] (1) Weigh stearic acid, stearyl glyceride, beeswax, and palm oil in proportion, heat in a water bath until melted, filter, and store at a constant temperature of 70-80°C;

[0047] (2) Weigh butanediol, ethanol, water, and triethanolamine in proportion, add them to the above solution, heat and stir in a water bath at 80° C., and emulsify for 10-20 minutes;

[0048] (3) Add the weighed nuciferine raw material and stir until the raw material and the cream are evenly mixed to obtain 0.5%, 1.0%, and 1.5% external creams.

[0049] 3. Establishment of natural hair loss model

[0050] (1) Experimental principle:

[0051] The hair growth of C57BL / 6 mice aged 7-8 weeks is stagnant and in the resting phase, so a natural hair growth model can be constructed. All the resting hairs are removed with wax paper to induce the hair follicles to enter the growth phase in a highly synchronous manner. The hair follicles are morphologically indistinguishable from the spontaneously formed growth phase follicles.

[0052] (2) Specific operations:

[0053] After the mice were weighed, 4% chloral hydrate was intraperitoneally injected at a dose of 10 μl / g BW (body weight). After the mice were anesthetized, the back hair was shaved with a shaver, and the 5.20 cm × 2.60 cm hair removal wax paper was warmed by hand and pasted from behind the ear to the tail along the hair growth direction of the mice. The legs were grasped with the left hand, and the hind legs were placed in the tiger's mouth with the front facing up, and the tail was pressed with the thumb, and the wax paper was quickly torn off from the tail with the right hand against the hair, and the back was wiped with wax removal wet paper.

[0054] Forty male C57BL / 6J mice were randomly divided into a model group, a 0.5% nuciferine group, a 1.0% nuciferine group, a 1.5% nuciferine group, and a 2.5% minoxidil group, with 8 mice in each group.

[0055] 4. Experimental study on the efficacy of nuciferine on the natural growth of hair in mice with natural hair loss

[0056] The drug was administered from the first day after hair removal, once a day, for 13 consecutive days. The commercially available minoxidil tincture had a concentration of 5%, which was diluted to 2.5% by adding an equal volume of anhydrous ethanol, and the dosage was 200 μl per head. The model group was smeared with a blank cream without drug; the nuciferine ointment group was administered with a concentration of 0.5%, 1.0%, and 1.5%, and the dosage was 0.2 g / head. Each time the drug was administered, a cotton swab was used to dip about 0.2 g of the ointment and apply it to the hair removal area.

[0057] On the 14th day after administration, the experimental mice were intraperitoneally injected with 10 μl / g BW 4% chloral hydrate. After the anesthesia of the mice was stable, the hairs were carefully plucking from 6 fixed points on the back of the mice with tweezers. About 10 hairs were plucking each time and placed on a clean white paper. The length was measured with a vernier caliper and the longest value was selected as the record value. The whole measurement process was repeated twice.

[0058] After the hair length measurement is completed, use a shaver to shave the grown hair in the depilatory area, collect it with weighing paper, and weigh the gross weight with a 1 / 100,000 electronic balance.

[0059] Growth factors, as a class of molecules that can promote cell proliferation and differentiation, have an important influence on the growth and development of hair. Growth factors such as IGF1, VEGF, EGF, and HGF can all be secreted by hair papilla cells. EGF can increase the level of β-catenin in the cell nucleus and activate Wnt10b, thereby stimulating the activity and growth of hair follicle outer root sheath cells; HGF is involved in stimulating the growth of mouse hair bulbs and hair shaft elongation; IGF1 can act on hair papilla cells to restore and maintain the potential for hair induction; VEGF participates in the growth and development of hair by forming blood vessels around hair follicles. Therefore, qPCR detection of hair growth-related growth factors was performed on the skin tissue after administration.

[0060] The skin tissue on the back of the mice was removed, RNA was extracted, reverse transcribed into cDNA, and qPCR amplification was performed using the SYBR Green dye method. The ΔΔCt method was used to calculate the Ct value to analyze the changes in the expression levels of growth factor-related genes. The relevant primer sequences are shown in Table 1:

[0061] Table 1 RT-qPCR primer sequences

[0062]

[0063] The relevant qPCR reaction system is shown in Table 2:

[0064] Table 2 RT-qPCR reaction system

[0065]

[0066] The relevant qPCR reaction procedures are shown in Table 3:

[0067] Table 3 qPCR reaction procedure

[0068]

[0069] 5. Experimental results

[0070] Hair length results Figure 1 As shown, compared with the model group, the nuciferine ointment group increased hair length in a dose-dependent manner and promoted hair growth, and the effect of 1.5% nuciferine was better than that of the positive drug minoxidil group.

[0071] The gross weight result is Figure 2 As shown, compared with the model group, the nuciferine ointment group increased hair weight in a dose-dependent manner, and the effect of 1.5% nuciferine was better than that of the positive drug minoxidil group.

[0072] The results of skin growth factor gene expression levels are as follows Figure 3As shown, compared with the model group, the expression levels of growth factor genes such as IGF1, VEGF, EGF, and HGF in the lotus leaf alkaloid ointment group were increased, indicating that it can stimulate cell growth, promote cell survival, and promote hair growth.

[0073] In summary, it can be seen that nuciferine has a significant effect in promoting hair growth in mice.

[0074] Example 2 Experimental evaluation of the therapeutic effect of nuciferine on alopecia model induced by chemotherapy

[0075] 1. Experimental Animals

[0076] The experimental animals were the same as in Example 1.

[0077] 2. Drug preparation

[0078] The preparation of 4% chloral hydrate and nuciferine ointment is the same as that in Example 1.

[0079] 8mg / ml cyclophosphamide injection (Andaosheng): 0.2g cyclophosphamide is dissolved in 25ml normal saline, vortexed and centrifuged, and injected intraperitoneally into mice after complete dissolution.

[0080] 3. Modeling of chemotherapy-induced hair loss

[0081] (1) Experimental principle:

[0082] The back hair of 7-8 week old C57 male mice was removed. On the 8th day after depilation, the newly formed hair follicles in all the depilated areas entered the growth stage VI. 80 mg / kg of cyclophosphamide was injected intraperitoneally once to induce an increase in apoptotic cells in the rapidly growing hair follicles, causing chemotherapy-induced alopecia in the newly formed hair of the mice.

[0083] (2) Specific operations:

[0084] The depilatory method is the same as in Example 1.

[0085] Forty-eight male C57BL / 6J mice were randomly divided into control group, model group, 0.5% nuciferine group, 1.0% nuciferine group, 1.5% nuciferine group, and 2.5% minoxidil group, with 8 mice in each group.

[0086] On the 8th day after hair removal, the hair entered the growth stage VI, and 80mg / kg of cyclophosphamide injection was injected intraperitoneally at 10μl / g BW, while the control group was injected with solvent saline. On the 5th day after cyclophosphamide injection, hair loss reached its most serious stage.

[0087] 4. Experimental study on the efficacy of nuciferine in a chemotherapy-induced hair loss model

[0088] The drug was administered from the first day after hair removal, once a day, for 13-14 consecutive days, and the experiment was terminated depending on the hair loss. The minoxidil group was administered at a dose of 200 μl per head. The control group and the model group were smeared with a blank cream without drug; the nuciferine ointment group was administered at a concentration of 0.5%, 1.0%, and 1.5%, with a dose of 0.2 g per head. Each time the drug was administered, a cotton swab was used to dip about 0.2 g of the ointment and applied to the hair removal area.

[0089] On the 13th day of administration, hair loss reached the most serious stage. On the 14th day, the experimental mice were intraperitoneally injected with 10μl / gB.W.4% chloral hydrate. After the mice were anesthetized, photos were taken under standard conditions to record the back skin condition and hair growth of each group of mice and score statistics. Scoring criteria: the proportion of the remaining hair area to the total area of ​​the hair loss area.

[0090] After the hair growth scoring is completed, use tweezers to carefully pick up the hair at 6 fixed locations on the back of the mouse, taking about 10 hairs each time, and place them on a clean white paper. Use a vernier caliper to measure the length and select the longest value as the record value. Repeat the entire measurement process twice.

[0091] After the hair length measurement is completed, use a shaver to shave the grown hair in the depilatory area, collect it with weighing paper, and weigh the gross weight with a 1 / 100,000 electronic balance.

[0092] 5. Experimental results

[0093] Hair growth score results Figure 4 As shown in the figure, compared with the blank control group, the growth score of the model group was significantly reduced, proving that the model was successful. Compared with the model group, the nuciferine ointment group could improve the hair growth score, and the effects of 0.5%, 1.0%, and 1.5% nuciferine groups were better than minoxidil. The experiment showed that nuciferine could apparently inhibit hair loss caused by chemotherapy agents.

[0094] The results of hair length and weight are as follows Figure 5 , Figure 6 As shown in the figure, compared with the blank control group, the hair length and weight of the model group were significantly reduced, proving that the model was successful. Compared with the model group, the nuciferine ointment group could significantly increase the hair length and weight, and the effects of 0.5%, 1.0%, and 1.5% nuciferine groups were better than minoxidil.

[0095] The above experimental results show that lotus leaf alkaloids can inhibit hair loss caused by chemotherapy drugs.

[0096] Example 3 Experimental evaluation of the therapeutic effect of nuciferine and its derivatives on the androgenic alopecia model of C57BL / 6 mice

[0097] 1. Experimental Animals

[0098] The experimental animals were the same as in Example 1.

[0099] 2. Drug preparation

[0100] The preparation of 4% chloral hydrate and nuciferine ointment is the same as that in Example 1.

[0101] 0.25% testosterone solution: Accurately weigh 0.25g of testosterone powder, add 70ml of anhydrous ethanol solution and 30ml of propylene glycol solution, dissolve completely, and store in a 4℃ refrigerator for later use.

[0102] Blank solvent: 35 ml of anhydrous ethanol solution and 15 ml of propylene glycol solution were evenly mixed to form 50 ml of blank solvent and stored in a 4°C refrigerator for later use.

[0103] 3. Modeling of androgenic alopecia

[0104] (1) Experimental principle:

[0105] The initial stage of establishing the androgenic alopecia model in C57BL / 6 mice is similar to the natural hair growth and hair removal mouse model. Starting from the second day after the back hair of 7-8 week old C57 male mice is removed, 0.25% testosterone solution is used daily to establish the model to inhibit hair growth.

[0106] (2) Specific operations:

[0107] The depilatory method is the same as in Example 1.

[0108] Forty-eight male C57BL / 6J mice were randomly divided into control group, model group, 0.5% nuciferine group, 1.0% nuciferine group, 1.5% nuciferine group, and 2.5% minoxidil group, with 8 mice in each group.

[0109] Starting from the first day after hair removal, the modeling agent was applied to the back of the hair removal area of ​​the mice, 200 μl / mouse, once a day, and the modeling continued for 14 days. The blank control group was applied with blank solvent, and the other groups were applied with 0.25% testosterone solution.

[0110] 4. Experimental study on the efficacy of nuciferine in the androgenic alopecia model

[0111] After modeling every day, the modeling agent was absorbed and applied to the back of the experimental mice. The drug was administered once a day for 14 consecutive days. The dose of minoxidil was 200 μl per mouse. The control group and the model group were smeared with a blank cream without drug; the concentration of nuciferine ointment in the group was 0.5%, 1.0%, and 1.5%, and the dosage was 0.2 g / mouse. Each time the drug was administered, a cotton swab was used to dip about 0.2 g of the ointment and apply it to the hair removal area.

[0112] On the 15th day after administration, the experimental mice were intraperitoneally injected with 10 μl / g 4% chloral hydrate. After the anesthesia of the mice was stable, the hairs were carefully plucking at 6 fixed points on the back of the mice with tweezers. About 10 hairs were plucking each time and placed on a clean white paper. The length was measured with a vernier caliper and the longest value was selected as the record value. The whole measurement process was repeated twice.

[0113] After the hair length measurement is completed, use a shaver to shave the grown hair in the depilatory area, collect it with weighing paper, and weigh the gross weight with a 1 / 100,000 electronic balance.

[0114] 5. Experimental results

[0115] The results of hair length and weight are as follows Figure 7 , Figure 8 As shown in the figure, compared with the blank control group, the hair length and weight of the model group were significantly reduced, proving that the model was successful. Compared with the model group, the nuciferine ointment group increased hair length and weight in a dose-dependent manner, and the effect of the 1.5% nuciferine group was better than that of minoxidil.

[0116] The above experimental results show that lotus leaf alkaloids can alleviate hair loss caused by androgen.

[0117] As described above, although the present invention has been shown and described with reference to specific preferred embodiments, it should not be construed as limiting the present invention itself. Various changes in form and details may be made without departing from the spirit and scope of the present invention as defined in the appended claims.

Claims

1. Use of nuciferine and its physiologically acceptable salts or solvates in the preparation of anti-hair loss and hair growth drugs.

2. The use according to claim 1, characterized in that The medicine is used in pharmaceutical preparations; the pharmaceutical preparations are used in preventing, caring for and treating thinning hair, hair loss and promoting hair health and growth.

3. The use according to claim 2, characterized in that: The pharmaceutical preparation comprises nuciferine and its physiologically acceptable salt or solvate and a pharmaceutically acceptable carrier or auxiliary material.

4. The use according to claim 2, characterized in that: The dosage form of the drug is cream, patch, ointment, cream preparation, gel or spray.

5. The use according to claim 2, characterized in that: The dosage form of the drug is tablets, granules, capsules, oral liquid preparations, pills, suspensions or dripping pills.

6. The use according to claim 2, characterized in that: The nuciferine and its physiologically acceptable salts or solvates account for 0.1-10 wt % of the total weight of the preparation.

7. The use according to claim 1, characterized in that The medicine is used for preventing and / or treating hair loss after chemotherapy; the medicine is used for preventing and / or treating androgenic alopecia.

8. The use according to claim 1, characterized in that The medicine is used in cosmetics, care products or beauty products; the cosmetics, care products or beauty products are selected from shampoo, hair conditioner, hair care essence, hair care oil, hair care lotion, scalp cream, hair care gel, hair spray, hair care mask or eyebrow care liquid.

9. The use according to claim 1, characterized in that The drug stimulates hair growth; the stimulation of hair growth includes accelerating the natural growth rate of hair, increasing hair length and weight, and promoting the growth of existing hair in a healthy state; the drug stimulates the expression and synthesis of growth factors, stimulates cell growth, promotes cell survival, and promotes hair growth.

Images